利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

255 条记录 (耗时 0.026 秒)

    Porous particles for deep lung delivery
    91.
    发明申请
    Porous particles for deep lung delivery 有权

    公开(公告)号：US20010033828A1

    公开(公告)日：2001-10-25

    申请号：US09888688

    申请日：2001-06-25

    申请人： The Penn Research Foundation, Inc.

    发明人： David A. Edwards ,  Giovanni Caponetti ,  Jeffrey S. Hrkach ,  Noah Lotan ,  Justin Hanes ,  Robert S. Langer ,  Abdellaziz Ben-Jebria

    IPC分类号： A61K038/28 ,  A61K031/715 ,  A61K048/00 ,  A61K009/00

    CPC分类号： A61K9/0075 ,  A61K9/1647 ,  A61K31/137 ,  Y10S514/826 ,  Y10S514/851

    摘要： Improved porous particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the porous particles are made of a biodegradable material and have a mass density less than 0.4 g/cm3/. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear null-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, porous particles having a relatively large mean diameter, for example greater than 5 nullm, can be used for enhanced delivery of a therapeutic agent to the alveolar region of the lung. The porous particles incorporating a therapeutic agent may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide variety of therapeutic agents.

    Alcohol-free transdermal insulin composition and processes for manufacture and use thereof
    96.
    发明申请
    Alcohol-free transdermal insulin composition and processes for manufacture and use thereof 失效
    无酒精透皮胰岛素组合物及其制造和使用方法

    公开(公告)号：US20040204343A1

    公开(公告)日：2004-10-14

    申请号：US10412637

    申请日：2003-04-11

    发明人： Robert Fishman

    IPC分类号： A61K038/28 ,  A61K009/70

    CPC分类号： A61K9/0014 ,  A61K38/28 ,  A61K47/14 ,  A61K47/32 ,  A61K47/44

    摘要： The instant invention is directed toward a dermal delivery system composition comprising an aqueous base vehicle including American Emu oil, Isopropyl Palmitate (PROTACHEM IPP), PEG-8 (a polyethylene glycol available under the tradename PROTACHEM 400), methylsulfonylmethane (MSM) and SEPIGEL 305 (a combination including polyacrylamide/C13-C-Iso-paraffin and LAURETH 7, in combination with a therapeutically effective amount of at least one species of insulin, and to processes for the manufacture and use thereof.

    摘要翻译： 本发明涉及一种真皮递送系统组合物，其包含含水基础载体，包括美国胭脂红油，棕榈酸异丙酯（PROTACHEM IPP），PEG-8（以商品名PROTACHEM 400获得的聚乙二醇），甲基磺酰甲烷（MSM）和SEPIGEL 305 （包括聚丙烯酰胺/ C13-C-异链烷烃和LAURETH 7的组合以及治疗有效量的至少一种胰岛素的组合，以及其制备和使用方法。

    Use of insulin for the treatment of cartilaginous disorders
    97.
    发明申请
    Use of insulin for the treatment of cartilaginous disorders 有权
    使用胰岛素治疗软骨疾病

    公开(公告)号：US20040138101A1

    公开(公告)日：2004-07-15

    申请号：US10740098

    申请日：2003-12-17

    申请人： Genentech, Inc.

    发明人： Ellen H. Filvaroff ,  Franklin W. Okumu

    IPC分类号： A61K038/28

    CPC分类号： A61K38/30 ,  A61K9/5031 ,  A61K38/28 ,  A61K38/55 ,  A61K39/3955 ,  A61K2300/00

    摘要： The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilaginous disorders, including arthritis, comprising the administration of insulin and/or insulin variants. Optionally, the administration may be in combination with a cartilage agent (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial, anti-inflammatory factor), in an extended- or sustained-release form. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilaginous disorders comprising the administration of insulin and/or insulin in combination with standard surgical techniques. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilaginous disorders comprising the administration of chondrocytes previously treated with an effective amount of insulin and/or insulin variant.

    摘要翻译： 本发明涉及用于治疗和修复软骨的方法，所述软骨包括损伤的软骨或包括关节炎的软骨疾病，包括施用胰岛素和/或胰岛素变体。 任选地，给药可以与延长或持续释放形式的软骨剂（例如肽生长因子，分解代谢拮抗剂，骨，滑膜，抗炎因子）组合。 或者，该方法提供了由损伤或软骨疾病损伤的软骨的治疗和修复，包括与标准手术技术组合施用胰岛素和/或胰岛素。 或者，该方法提供了由损伤或软骨疾病损伤的软骨的治疗和修复，包括施用以前用有效量的胰岛素和/或胰岛素变体治疗的软骨细胞。

    Dipeptidyl peptidase IV inhibiting fluorinated cyclic amides
    99.
    发明申请
    Dipeptidyl peptidase IV inhibiting fluorinated cyclic amides 审中-公开
    二肽基肽酶IV抑制氟化环状酰胺

    公开(公告)号：US20040110817A1

    公开(公告)日：2004-06-10

    申请号：US10713299

    申请日：2003-11-13

    申请人： Pfizer Inc

    发明人： Bernard Hulin

    IPC分类号： A61K038/28 ,  A61K031/555 ,  A61K031/426 ,  A61K031/155 ,  C07D207/46

    CPC分类号： C07D207/22

    摘要： The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

    摘要翻译： 本发明涉及酶二肽基肽酶-IV的新的治疗活性和选择性抑制剂，包含该化合物的药物组合物以及这些化合物用于治疗与受DPP-IV加工的蛋白质相关的疾病的用途，例如类型 2型糖尿病，高血糖，葡萄糖耐量异常，代谢综合征（X综合征或胰岛素抵抗综合征），糖尿病，代谢性酸中毒，白内障，糖尿病性神经病变，糖尿病性肾病，糖尿病性视网膜病变，糖尿病性心肌病，1型糖尿病，肥胖，肥胖症加重 ，高血压，高脂血症，动脉粥样硬化，骨质疏松症，骨质减少，虚弱，骨质流失，骨折，急性冠状动脉综合征，多囊卵巢综合症不育症，短肠综合征，焦虑症，抑郁症，失眠症，慢性疲劳，癫痫，进食障碍，慢性疼痛 ，酒精成瘾，与肠蠕动相关的疾病，溃疡，溃疡 表肠综合征，炎性肠综合征和预防2型糖尿病的疾病进展。 本发明还涉及鉴定糖尿病的胰岛素促分泌剂的方法。

    Mixed fibrils
    100.
    发明申请
    Mixed fibrils 审中-公开
    混合原纤维

    公开(公告)号：US20040096852A1

    公开(公告)日：2004-05-20

    申请号：US10432344

    申请日：2003-11-20

    发明人： Chris Dobson ,  Catherine Macphee

    IPC分类号： C12Q001/68 ,  G01N033/53 ,  A61K039/395 ,  C07K014/47 ,  A61K048/00 ,  A61K038/28

    CPC分类号： C07K14/4711

    摘要： Fibrils of two or more different peptides are disclosed; these peptides can be related or unrelated. They have a variety of uses as biomaterials and nanomaterials.

    摘要翻译： 公开了两种或更多种不同肽的原纤维; 这些肽可以是相关的或不相关的。 它们具有生物材料和纳米材料的多种用途。